PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
3.300
-0.060 (-1.79%)
Nov 1, 2024, 4:00 PM EDT - Market closed
PolyPid Employees
As of December 31, 2023, PolyPid had 62 total employees, including 59 full-time and 3 part-time employees. The number of employees increased by 2 or 3.33% compared to the previous year.
Employees
62
Change (1Y)
2
Growth (1Y)
3.33%
Revenue / Employee
n/a
Profits / Employee
-$398,419
Market Cap
22.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Retractable Technologies | 151 |
Pieris Pharmaceuticals | 50 |
Movano | 30 |
Spruce Biosciences | 29 |
MEI Pharma | 28 |
Chemomab Therapeutics | 20 |
NeuroBo Pharmaceuticals | 8 |
XTL Biopharmaceuticals | 7 |
PYPD News
- 2 days ago - PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 - GlobeNewsWire
- 11 days ago - PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery - GlobeNewsWire
- 4 weeks ago - PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - GlobeNewsWire
- 2 months ago - PolyPid to Participate in Three Upcoming Fall Investor Conferences - GlobeNewsWire
- 2 months ago - PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds - GlobeNewsWire
- 3 months ago - PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 - GlobeNewsWire
- 5 months ago - PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial - GlobeNewsWire